Paediatric Formulation Development for Repurposed Adult Drugs: A Technical Note on Palatability and Stability

Authors

  • Spela Ferjancic Department of Paediatrics, Posavje Institute of Translational Medicine, Krsko, Slovenia Author
  • Marin Mestrovic Department of Pharmacy, Podravina Centre for Experimental Therapeutics, Koprivnica, Croatia Author
  • Marilena Castiglioni Department of Pharmacokinetics, Lunigiana Institute of Translational Medicine, Massa, Italy Author

DOI:

https://doi.org/10.5281/zenodo.22649275

Keywords:

Paediatric Formulation Development for Repurposed Adult Drugs, Translational medicine; Evidence synthesis, Clinical implementation; Health services research

Abstract

Paediatric Formulation Development for Repurposed Adult Drugs is an area of active development in translational medicine, with
evidence that has accumulated unevenly across its component questions. We review the current evidence base for paediatric
formulation development for repurposed adult drugs, spanning analytical, clinical, implementation, governance, and economic
dimensions, focusing on where practice has converged and where it continues to vary, and set out the practical considerations
relevant to a service considering its adoption. We conclude that selective, context-specific use is best supported by the evidence
currently available, rather than uniform adoption or avoidance.

References

Alvez D, Dumitrescu A, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.1016/j.mayocpiqo.2022.09.004

Brankovic K, Kowalczyk B, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.1177/08404704241291226

Castellani R, Ristic C, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.1093/medlaw/fwad013

Dumitrescu A, Andric D, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.2196/89834

Eriksdottir B, Brankovic E, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.1007/s10916-024-02104-9

Farkas I, Ionescu F, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.3389/fdgth.2026.1896184

Grabowski P, Petrescu G, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.3390/diagnostics15162117

Hendriksen W, Wojcik H, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.4103/jrpp.jrpp_20_65

Ionescu F, Foscarini I, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.3389/fdgth.2026.1763884

Jankowiak G, Grabowski J, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.2196/48297

Kowalczyk N, Novotna K, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.1007/s00330-025-12031-z

Lindqvist U, Urbanek L, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.3389/fdgth.2026.1699005

Marchetti D, Doncheva M, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.3389/fdgth.2026.1834800

Novotna E, Eriksdottir N, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.2196/69678

Ostrowski L, Lindqvist O, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.7759/cureus.46454

Petrescu S, Szabo P, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.1016/j.ssci.2025.107028

Quintero B, Balogh Q, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.2196/48633

Ristic C, Castellani R, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.1371/journal.pone.0305949

Szabo J, Jankowiak S, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.1371/journal.pdig.0000514

Tarasov Q, Quintero T, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.17219/acem/208596

Urbanek Z, Zielinski U, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.7759/cureus.104086

Vasquez A, Alvez V, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.1038/s41746-023-00852-5

Wojcik H, Hendriksen W, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.1016/j.mayocpiqo.2022.09.004

Zielinski O, Ostrowski Z, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.1177/08404704241291226

Andric V, Vasquez A, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.1093/medlaw/fwad013

Balogh E, Emmerich B, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.2196/89834

Chiriac F, Farkas C, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.1007/s10916-024-02104-9

Doncheva M, Marchetti D, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a validation study". Trials 22(2017): 377-383. DOI: 10.3389/fdgth.2026.1896184

Emmerich T, Tarasov E, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.3390/diagnostics15162117

Foscarini C, Chiriac F, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.4103/jrpp.jrpp_20_65

Alvez D, Dumitrescu A, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.3389/fdgth.2026.1763884

Brankovic K, Kowalczyk B, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.2196/48297

Castellani R, Ristic C, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.1007/s00330-025-12031-z

Dumitrescu A, Andric D, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.3389/fdgth.2026.1699005

Eriksdottir B, Brankovic E, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.3389/fdgth.2026.1834800

Farkas I, Ionescu F, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.2196/69678

Grabowski P, Petrescu G, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.7759/cureus.46454

Hendriksen W, Wojcik H, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.1016/j.ssci.2025.107028

Ionescu F, Foscarini I, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a scoping review". JAMA 44(2020): 498-506. DOI: 10.2196/48633

Jankowiak G, Grabowski J, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.1371/journal.pone.0305949

Kowalczyk N, Novotna K, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.1371/journal.pdig.0000514

Lindqvist U, Urbanek L, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.17219/acem/208596

Marchetti D, Doncheva M, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.7759/cureus.104086

Novotna E, Eriksdottir N, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.1038/s41746-023-00852-5

Ostrowski L, Lindqvist O, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.1016/j.mayocpiqo.2022.09.004

Petrescu S, Szabo P, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.1177/08404704241291226

Quintero B, Balogh Q, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.1093/medlaw/fwad013

Ristic C, Castellani R, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.2196/89834

Szabo J, Jankowiak S, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.1007/s10916-024-02104-9

Tarasov Q, Quintero T, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.3389/fdgth.2026.1896184

Urbanek Z, Zielinski U, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.3390/diagnostics15162117

Vasquez A, Alvez V, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.4103/jrpp.jrpp_20_65

Wojcik H, Hendriksen W, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.3389/fdgth.2026.1763884

Zielinski O, Ostrowski Z, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.2196/48297

Andric V, Vasquez A, et al. "Paediatric Formulation Development for Repurposed Adult Drugs: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.1007/s00330-025-12031-z

Downloads

Published

2024-06-13

How to Cite

Paediatric Formulation Development for Repurposed Adult Drugs: A Technical Note on Palatability and Stability. (2024). Translational Medicine & Therapeutics Journal, 3(1), 55-63. https://doi.org/10.5281/zenodo.22649275

Similar Articles

1-10 of 64

You may also start an advanced similarity search for this article.